Roche Holding AG/€ROG
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Roche Holding AG
Roche Holding AG is a Swiss multinational healthcare company based in Basel, Switzerland, specializing in pharmaceuticals and diagnostics. The company's pharmaceutical division is renowned for developing innovative medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche's diagnostics segment offers products and services for research and medical applications, including in vitro diagnostics and instruments for hospitals, labs, and physicians. Founded in 1896, Roche has a significant global presence, operating in numerous countries worldwide. The company is strategically positioned through its focus on personalized healthcare, leveraging its expertise in both pharmaceuticals and diagnostics to deliver tailored treatment solutions.
Ticker
€ROG
Sector
Primary listing
XGAT
Employees
103,249
Headquarters
Basel, Switzerland
Website
Roche Holding AG Metrics
BasicAdvanced
€252B
22.91
€12.70
0.18
€10.14
3.49%
Price and volume
Market cap
€252B
Beta
0.18
52-week high
€326.58
52-week low
€247.15
Average daily volume
1.6K
Dividend rate
€10.14
Financial strength
Current ratio
1.294
Quick ratio
0.884
Long term debt to equity
84.935
Total debt to equity
104.809
Dividend payout ratio (TTM)
81.99%
Interest coverage (TTM)
16.47%
Profitability
EBITDA (TTM)
25,326.749
Gross margin (TTM)
74.79%
Net profit margin (TTM)
14.85%
Operating margin (TTM)
31.94%
Effective tax rate (TTM)
21.55%
Revenue per employee (TTM)
€659,410
Management effectiveness
Return on assets (TTM)
13.30%
Return on equity (TTM)
31.32%
Valuation
Price to earnings (TTM)
22.906
Price to revenue (TTM)
3.375
Price to book
7.6
Price to tangible book (TTM)
50.14
Price to free cash flow (TTM)
16.221
Free cash flow yield (TTM)
6.16%
Free cash flow per share (TTM)
17.927
Dividend yield (TTM)
3.49%
Forward dividend yield
3.49%
Growth
Revenue change (TTM)
4.80%
Earnings per share change (TTM)
-11.28%
3-year revenue growth (CAGR)
-2.08%
10-year revenue growth (CAGR)
2.35%
3-year earnings per share growth (CAGR)
-12.59%
10-year earnings per share growth (CAGR)
1.24%
3-year dividend per share growth (CAGR)
1.41%
10-year dividend per share growth (CAGR)
1.95%
Bulls say / Bears say
Roche beat H1 2025 operating profit forecasts with a 6 % rise to CHF 12 billion (11 % CER), driven by Phesgo sales up 55 % to CHF 1.2 billion and Xolair up 34 % to CHF 1.45 billion, demonstrating strong execution in key therapeutic franchises (Reuters).
Roche plans to launch a late-stage trial investigating its BrainShuttle antibody trontinemab for Alzheimer’s prevention or delay, leveraging novel CNS delivery technology to target a high-unmet-need market and complement diagnostics capabilities (Reuters).
Roche’s commitment to invest USD 50 billion in U.S. R&D and manufacturing over five years will create over 12,000 jobs and bolster U.S. supply chain resilience, positioning the company favorably amid potential tariff risks and strengthening its largest market presence (Reuters).
Diagnostics division revenue remained flat at CHF 7 billion in H1 2025, with gains in pathology solutions offset by pricing reforms in China, highlighting limited growth diversification in non-pharma segments (Reuters).
Roche’s Phase III MUSETTE trial of a higher-dose formulation of its MS drug Ocrevus failed to meet its primary endpoint, curbing prospects for expanding usage and extending the product’s lifecycle beyond the standard 600 mg dose (Reuters).
In Alzheimer’s research, Roche’s trontinemab faces intensified competition as Eli Lilly’s Kisunla received an EMA recommendation and Biogen/Eisai’s Leqembi remains established, potentially limiting Roche’s market share in a crowded field (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Roche Holding AG stock?
Roche Holding AG (ROG) has a market cap of €252B as of October 26, 2025.
What is the P/E ratio for Roche Holding AG stock?
The price to earnings (P/E) ratio for Roche Holding AG (ROG) stock is 22.91 as of October 26, 2025.
Does Roche Holding AG stock pay dividends?
Yes, the Roche Holding AG (ROG) stock pays dividends to shareholders. As of October 26, 2025, the dividend rate is €10.13635 and the yield is 3.49%. Roche Holding AG has a payout ratio of 81.99% on a trailing twelve-month basis.
When is the next Roche Holding AG dividend payment date?
The next Roche Holding AG (ROG) dividend payment date is unconfirmed.
What is the beta indicator for Roche Holding AG?
Roche Holding AG (ROG) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.